MeSH D011658 - pulmonary fibrosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Pirfenidone | Pirfenidone | 2022-01-25 | |||
| Roche | Pirfenidone | Esbriet | 2011-02-27 | $749.525 M | Y2022 | |
| Sandoz | Pirfenidone | Pirfenidone | 2022-04-28 | |||
| Alembic Pharmaceuticals | Pirfenidone | Pirfenidone | 2022-05-20 | |||
| Hetero | Pirfenidone | Pirfenidone | 2022-09-21 | |||
| Amneal Pharmaceuticals | Pirfenidone | Pirfenidone | 2022-01-03 | |||
| Accord Healthcare | Pirfenidone | Pirfenidone | 2022-01-25 | |||
| MSN Laboratories | Pirfenidone | Pirfenidone | 2022-05-24 | |||
| Micro Laboratories | Pirfenidone | Pirfenidone | 2022-05-18 | |||
| Laurus Labs | Pirfenidone | Pirfenidone | 2022-07-19 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
80%8/10
Phase 2
45%15/33
Phase 3
19%4/21
Approved: 1Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use